Nuveen Asset Management LLC grew its position in shares of BioNTech SE (NASDAQ:BNTX – Get Rating) by 36.7% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 208,395 shares of the company’s stock after buying an additional 55,925 shares during the period. Nuveen Asset Management LLC owned 0.09% of BioNTech worth $28,108,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds also recently made changes to their positions in BNTX. Eagle Bay Advisors LLC bought a new position in BioNTech during the second quarter worth about $33,000. Heritage Wealth Management LLC purchased a new position in BioNTech in the 2nd quarter valued at approximately $36,000. Huntington National Bank purchased a new stake in BioNTech during the 3rd quarter worth about $34,000. Activest Wealth Management grew its stake in BioNTech by 39,000.0% during the third quarter. Activest Wealth Management now owns 391 shares of the company’s stock valued at $53,000 after acquiring an additional 390 shares in the last quarter. Finally, Great West Life Assurance Co. Can bought a new position in shares of BioNTech in the third quarter worth $62,000. Institutional investors own 15.29% of the company’s stock.
Wall Street Analyst Weigh In
BNTX has been the subject of a number of research analyst reports. The Goldman Sachs Group dropped their price objective on shares of BioNTech from $177.00 to $156.00 and set a “neutral” rating for the company in a report on Tuesday, January 31st. UBS Group set a $168.00 price target on BioNTech in a research report on Wednesday, February 1st. Bank of America raised BioNTech from a “neutral” rating to a “buy” rating and set a $239.00 price objective for the company in a research report on Thursday, December 15th. Canaccord Genuity Group cut their price objective on shares of BioNTech from $200.00 to $191.00 and set a “buy” rating on the stock in a report on Tuesday, November 8th. Finally, JPMorgan Chase & Co. lowered their target price on shares of BioNTech from $148.00 to $142.00 and set a “neutral” rating for the company in a report on Wednesday, February 8th. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the company. According to MarketBeat.com, BioNTech presently has a consensus rating of “Moderate Buy” and an average target price of $206.69.
BioNTech Price Performance
BioNTech Profile
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer.
Featured Articles
- Get a free copy of the StockNews.com research report on BioNTech (BNTX)
- Lucira Stock Jumps over 250% on FDA Approval, Beware Chapter 11
- Will Q4 Results Send Zoom Video Stock Higher?
- Is Amazon a Blue Chip Stock?
- Occidental Petroleum Pulls Back To The Sweet Spot
- Should You Take a Cruise in Royal Caribbean Stock?
Want to see what other hedge funds are holding BNTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioNTech SE (NASDAQ:BNTX – Get Rating).
Receive News & Ratings for BioNTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioNTech and related companies with MarketBeat.com's FREE daily email newsletter.
